STOCK TITAN

2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
2seventy bio, Inc. to announce Q2 2023 financial results on August 14, 2023 and host conference call and webcast for business update.
Positive
  • 2seventy bio, Inc. will announce its second quarter 2023 financial results on August 14, 2023.
  • The company will host a conference call and webcast to discuss the results and provide a business update.
  • Participants can access the conference call live via webcast on the company's website.
  • A replay of the call will be available on the company's website.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update.

Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It’s recommended that participants join 10 minutes prior to the event’s start. A replay of the call will be available on the 2seventy bio website following the completion of the call.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.

With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

Media & Investors:

Jenn Snyder

617-448-0281

jenn.snyder@2seventybio.com

Morgan Adams

774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

When will 2seventy bio announce its Q2 2023 financial results?

2seventy bio will announce its second quarter 2023 financial results on August 14, 2023.

How can participants access the conference call?

Participants can access the conference call live via webcast on the company's website.

Will there be a replay of the conference call?

Yes, a replay of the call will be available on the company's website.

2seventy bio, Inc.

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Stock Data

192.94M
49.50M
4.06%
90.89%
10.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE